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Abstract  The  authors  report  a  case  of  Trousseau’s  syndrome  presenting  in  a  previously  asymp-
tomatic 58-year-old  man  diagnosed  with  pancreatic  adenocarcinoma  and  liver  metastases
during a  workup  prompted  by  migratory  venous  thrombosis  and  pulmonary  embolism.  It  was
followed by  an  ischaemic  stroke  that  occurred  while  the  patient  was  just  one  day  off  antico-
agulant  therapy  with  low-molecular-weight  heparin  to  allow  for  liver  and  pancreatic  biopsies.
Trousseau’s  syndrome  is  deﬁned  by  recurrent  or  migratory  venous  thrombosis,  arterial  embolism
caused  by  non-bacterial  thrombotic  endocarditis,  or  both,  in  patients  with  underlying  malig-
nancy. Treatment  relies  on  the  lifelong  administration  of  heparin,  and  its  interruption  --  however
brief --  may  promote  new  thrombotic  events.
© 2012  Sociedade  Portuguesa  de  Gastrenterologia  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Síndrome  de  Trousseau  por  adenocarcinoma  do  pâncreas  assintomático
Resumo  Os  autores  relatam  um  caso  de  Síndrome  de  Trousseau,  manifestado  por  trom-
bose venosa  migratória  e  embolia  pulmonar,  num  doente  de  58  anos  assintomático  até  à
data de  internamento.  O  estudo  desencadeado  revela  adenocarcinoma  do  pâncreas  comHeparina;
Neoplasia  maligna
oculta;
Adenocarcinoma
pancreático
metástases  hepáticas,  e  a  situac¸ão  torna-se  ainda  mais  grave  após  a  ocorrência  de  um  aci-
dente vascular  cerebral  isquémico,  aparentemente  em  relac¸ão  com  a  paragem  por  24  horas
da terapêutica  anti-coagulante  com  heparina  de  baixo  peso  molecular  para  realizac¸ão  de
biópsia hepática  e  pancreática  guiadas  por  exame  de  imagem.  A  síndrome  de  Trousseau
deﬁne-se por  tromboses  venosas  recorrentes  ou  migratórias,  embolias  arteriais  causadas
por endocardite  trombótica  não-bacteriana,  ou  ambas,  em  doentes  com  neoplasia  maligna
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subjacente.  O  tratamento  implica  a  administrac¸ão  permanente  de  heparina,  e  qualquer
interrupc¸ão −ainda  que  breve−  pode  proporcionar  novo  episódio  de  trombose.
© 2012  Sociedade  Portuguesa  de  Gastrenterologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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(Introduction
Trousseau’s  syndrome  (TS),  named  after  the  French  physi-
cian  Armand  Trousseau  who  ﬁrst  described  it  in  1865,
refers  to  recurrent  or  migratory  spontaneous  venous  throm-
bosis,  arterial  embolism  due  to  non-bacterial  thrombotic
endocarditis,  or  both,  in  a  patient  with  known  or  occult
malignancy  which  is  usually  difﬁcult  to  diagnose  and  may
even  remain  elusive  until  it  is  disclosed  in  an  autopsy.1
Thrombosis  can  occur  from  months  to  years  before  can-
cer  is  known,  and  a  negative  thorough  initial  work-up  does
not  forgo  the  need  for  continued  evaluation  that  will  ulti-
mately  allow  an  earlier  diagnosis.2,3 Cryptogenic  thrombosis
prevented  by  heparin  but  not  oral  anticoagulants  should
prompt  doctors  to  investigate  the  possibility  of  underly-
ing  malignancy.  Patients  with  TS  show  persistent  low-grade
intravascular  coagulation,  thus  accounting  for  the  need  to
treat  them  with  full  large  dose  low  molecular  weight  heparin
on  a  lifelong  basis.4
These  patients  show  thrombotic  diathesis  that  can  be
devastating  when  left  untreated,  and  the  most  severe  cases
may  lead  to  limb  amputation  in  just  a  few  hours,  as  a
result  of  severe  disseminated  intravascular  coagulation  (DIC)
that  can  happen  before  an  actual  thrombosis  ensues.  Par-
ticular  forms  of  this  syndrome  are  phlegmasia  alba  dolens
and  phlegmasia  cerulea  dolens,5 and  a  variant  of  classic  TS
has  been  identiﬁed,  combining  multiple  arterial  and  venous
thrombi  with  DIC  prone  to  bleeding.6
Malignant  neoplasms  are  pro-thrombotic,  and  anoma-
lies  are  possible  in  each  point  of  Virchow’s  triad  --  blood
ﬂow  (stasis),  components  (hypercoagulability)  or  vessel  wall
(endothelial  injury).  These  surely  are  synergistic  forces
behind  this,  and  many  other  factors  such  as  concomitant
diseases,  medications  and  decreased  motility  have  a role
as  contributing  factors.7,8 TS  involves  marked  changes  in
the  clotting  cascade,  brought  about  by  the  production
and  release  of  procoagulant  substances  from  tumour  cells.
Although  it  may  be  associated  with  any  kind  of  neoplasm,  TS
is  most  often  related  to  pancreatic,  lung,  prostate,  gastric,
colorectal,  ovarian  and  breast  cancer.9
Clinical report
Present  illness
A  58-year-old  man,  electronics  technician,  was  admitted  in
our  Internal  Medicine  ward  with  deep  venous  thrombosis  of
the  right  lower  limb.  He  presented  to  the  Emergency  Depart-
ment  with  a  3-day  course  of  right  calf  pain  worsened  by
walking,  followed  by  swelling  and  increased  temperature  in
m
(
A
lhe  same  limb.  Throughout  the  whole  period  he  felt  increas-
ng  fatigue  and  had  an  episode  of  fainting.  Just  four  days
efore  the  current  symptoms  started  he  had  arrived  from
 vacation  in  Ecuador,  during  which  his  right  upper  limb
ad  become  swollen,  red  and  hot.  He  was  diagnosed  with
ight  arm  cellulitis  and  was  started  on  antibiotic  and  anti-
nﬂammatory  therapy,  improving  subsequently.  He  denied
ever,  sweating,  weight  loss  or  coughing,  as  well  as  any
igestive,  urinary  or  other  musculoskeletal  symptoms.
ast  medical  history
ast  medical  history  was  positive  for  some  childhood  infec-
ious  diseases  (measles,  mumps,  chicken  pox),  grade  I
rterial  hypertension  (known  for  21  years  and  without  med-
cation),  smoking  habits  (20  pack-year  units),  mild  alcohol
ntake  (20  g  daily),  chronic  lumbar  disc  disease,  left  varic-
cele  surgery  (at  the  age  of  21)  and  benign  prostatic
ypertrophy.
amily  diseases
is  father  deceased,  with  a  history  of  chronic  renal  fail-
re.  There  were  no  discernible  accounts  of  cancer  in  close
elatives.
hysical  examination
is  physical  examination  revealed  great  overall  condi-
ion  and  stable  vital  signs  (BP  113/70  mmHg,  HR  70  bpm,
R  20  bpm,  apyrexia);  no  skin  lesions,  lymphadenopathy
r  thyromegaly;  normal  cardiac  and  respiratory  sounds;
oft,  nontender,  nondistended  abdomen  with  normal  bowel
ounds,  no  masses  on  abdominal  examination,  and  no  hep-
tosplenomegaly;  no  evidence  of  infection  in  his  right  upper
imb;  slight  swelling  and  increased  temperature  in  his  right
eg,  with  positive  Homans’  sign;  normal  neurologic  exam  and
undus  observation  within  normal  limits.
ab  tests
aboratory  tests  showed  the  following:  haemoglobin
4.6  g/dl;  WBC  10.9  ×  109/l  (68.1%N--20.3%L--7.1%M--4%E);
latelets  258.0  ×  109/l;  ESR  13  mm;  CRP  3.5  mg/dl  (N  <  1);
ransferrin  195  mg/dl  (N:  215--365);  ferritin  344.9  ng/ml
26.0--388.0);  glucose  84  mg/dl;  creatinine  0.6  mg/dl;  albu-
in  3.7  g/dl;  normal  serum  electrophoresis;  AST  42  U/l
17--59);  ALT  65  U/l  (21--72);  GGT  168  U/l  (N:  15--73);
LP  209  U/l  (N:  38--126);  total  bilirubin  0.4  mg/dl;  amy-
ase  591  U/l  (N:  30--110);  lipase  6356  U/l  (N:  23--300);
174  A.  Murinello  et  al.
Figure  1  Contrast-enhanced  abdominal  CT  scan,  axial  view:
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Figure  2  Contrast-enhanced  abdominal  CT  scan,  axial
v
(
s
(
T
H
q
O
T
O
g
c
with  hepatic  metastases  (Fig.  4).  In  order  to  safely  undergo
these  biopsies  enoxaparin  was  withheld  during  24  h.  About
3  days  after  low-molecular-weight  heparin  (LMWH)  was
stopped  the  patient  suffered  a  severe  ischaemic  stroke  leav-ypovascular  lesions  of  the  liver  compatible  with  metastatic
nﬁltration.
DH  704  U/l  (N:  303--618);  total  cholesterol  180  mg/dl;
riglycerides  122  mg/dl;  total  calcium  9.5  mg/dl;  INR  1.1;
PTT  38.0′ ′;  factor  V  130.5%;  factor  VIII  152.2%;  protein
 97%;  protein  S  92.8%;  antithrombin  III  107%;  resistance
o  activated  protein  C  3.14  (within  normal  limits);  Lupus
nticoagulant  1.94  ratio  (1.6--2.0),  Silica  clotting  time  1.26
atio  (>1.16:  positive);  negative  antinuclear  antibodies  and
nti  2-glycoprotein;  negative  VDRL;  normal  TSH;  nega-
ive  serologies  for  both  hepatitis  B  and  C.  Human  chorionic
onadotropin  116  (N  <  5)  and  CA  15.3  =  74.4  U/ml  (N  <  31);  all
ther  tumour  markers  (PSA,  -fetoprotein,  CA  19.9  and  CEA)
ithin  normal  range.  Normal  urinalysis.
ardiac  tests
ardiac  tests  showed  the  following:  (1)  EKG  --  normal;  (2)
ardiac  ultrasound  displaying  good  left  ventricle  global  sys-
olic  function;  diastolic  dysfunction;  no  valve  abnormalities;
ild  biatrial  dilation;  dilated  right  ventricle  with  preserved
ystolic  function;  IVC  within  normal  limits,  preserved  inspi-
atory  collapse;  no  intra-chamber  thrombi  or  tumour.
adiologic  exams
adiologic  exams  revealed:  (1)  chest  radiograph  --  normal;
2)  venous  ultrasound  and  Doppler  of  the  lower  limbs;  (3)
horacic  CT-angiogram  and  (4)  abdominal  and  pelvic  CT  scan.
he  last  three  exams  lead  to  the  following  diagnoses:  (A)
esidual  superﬁcial  venous  thrombosis  of  the  right  basilic
ein,  maintaining  deep  venous  (humeral  and  axillary)  system
ermeability;  (B)  deep  venous  thrombosis  of  the  right  pos-
erior  tibial  and  calf  veins,  with  normal  popliteal,  common
emoral,  superﬁcial  femoral  vein,  great  saphenous  and  small
aphenous  vein  permeability;  left  lower  limb  venous  system
ith  no  lesions;  (C)  anterior  segmental  pulmonary  embolismn  the  right  upper  lobe  and  the  internal  segmental  branch  of
he  ipsilateral  inferior  lobe;  (D)  enlarged  liver  with  several
mages  compatible  with  metastases  (Fig.  1);  and  (E)  inﬁltra-
ive  lesion  of  the  pancreatic  uncinate  process,  involving  the
F
1
a
ciew: hypovascular  lesion  of  the  pancreatic  uncinate  process
2.5 cm  Ø),  with  involvement  of  the  superior  mesenteric  vessels.
uperior  mesenteric  vessels  and  thus  becoming  inoperable
Fig.  2).
reatment
e  was  treated  with  subcutaneous  enoxaparin  60  mg  bid,
12  h,  with  subsequent  improvement.
utcome
he  patient  was  then  transferred  to  the  Lisbon  Portuguese
ncology  Institute,  where  he  had  an  endoscopic  ultrasound
uided  ﬁne-needle  aspiration  biopsy  of  the  liver  and  pan-
reas  that  conﬁrmed  a  pancreatic  adenocarcinoma  (Fig.  3)igure  3  Pancreatic  aspiration  cytology,  Papanicolaou  stain
0 ×  40:  small  tridimensional  aggregate  showing  atypical  cells  of
denocarcinoma,  displaying  nuclear  pleomorphism  and  hyper-
hromasia.
Trousseau’s  syndrome  due  to  asymptomatic  pancreatic  adenocar
Figure  4  Hepatic  aspiration  cytology,
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TMay--Grünwalds--Giemsa  stain  10  ×  40:  small  aggregate  of
atypical  cells  with  a  coarsely  papillary  conﬁguration  and  with
distinct  nuclear  pleomorphism.
ing  him  with  right-side  hemiplegia.  Progressive  deterioration
in  neurologic  status  quickly  ensued  and  the  patient  eventu-
ally  died  a  few  days  afterwards.  No  autopsy  was  made.
Discussion
The  combination  of  conventional  tumour  markers,  endo-
scopic  methods  and  the  most  recent  radiologic  means
including  positron-emitting  tomography  (PET  scan)  allow  us
to  correctly  diagnose  the  malignancy  behind  TS  in  about
85--95%  of  cases.9 We  stress  the  pivotal  need  --  as  we
approach  these  patients  in  medical  wards  --  to  quickly  and
correctly  identify  the  origin  and  histology  of  the  underlying
neoplasm,  because  TS  is  a  quite  serious  clinical  condition,
and  even  though  it  is  usually  associated  with  advanced-stage
cancer,  there  are  also  rare  events  when  it  helps  to  uncover
cancer  in  an  early  phase  and  treat  it,  allowing  for  a  bet-
ter  prognosis.10,11 Lifelong  anticoagulation  with  heparin  is
mandatory,  with  an  initial  period  of  high  dosage  ranging  from
15  to  90  days  according  to  different  authors.12,13 Abruptly
interrupting  heparin  without  previous  tumour  regression  can
be  catastrophic,  because  procoagulating  substances  con-
tinue  to  be  released  by  cancer  cells,  thus  maintaining  their
prothrombotic  effect.  Withholding  heparin  for  just  a  few
hours  can  reactivate  the  clotting  cascade  and  precipitate
thrombotic  events.2,14 Vitamin  K  antagonists  are  not  effec-
tive  in  preventing  these  episodes,  since  the  procoagulants
released  by  neoplastic  cells  do  not  depend  on  this  vitamin,
and  should  not  be  used  in  this  context.2
There  are  several  explanations,  probably  true  to  some
degree  and  most  likely  intertwined,15 to  these  prothrom-
botic  effects  in  TS.  Some  of  these  are:  (1)  high  serum
levels  of  tissue  factor,  a  primary  cellular  initiator  of
blood  clotting,  primarily  converting  factor  VII  to  its  active
form  which  then  actives  other  proteases  related  to  this
process,  particularly  factor  X;  (2)  intratumour  secretion
of  a  cystein-proteinase,  activating  factor  X  even  in  the
absence  of  factor  VII;  (3)  cancer  cell  hypoxia,  the  subse-
quent  microenvironmental  stress  leading  to  the  secretion
of  procoagulant  and  angiogenic  factors,  not  only  increasing
Rcinoma  175
xpression  of  clotting-enabling  genes  but  also  correlating
hrombotic  processes  and  metastatic  disease;  (4)  platelet-
ich  microthrombotic  processes;  (5)  activation  of  oncogenes
hat  induce  clotting;  (6)  toxicity  from  high  environmental
evels  of  iron,  possibly  contributing  to  the  start  and  pro-
otion  of  the  tumour  process  while  also  instigating  lipid
xidative  lesions,  resulting  in  an  increased  expression  of  tis-
ue  factor  and  a  down-regulation  of  its  inhibitory  pathway;
7)  indirect  effect  of  inﬂammatory  cytokines,  encouraged
y  tumour  cells,  able  to  worsen  TS  by  activating  endothelial
ells  and  subsequently  increasing  the  expression  of  adhe-
ion  molecules  including  P-selectin;  (8)  putative  action  of
ucines  produced  by  some  neoplasms,  possibly  connecting
o  P-selectin  and  L-selectin  which  then  would  promote  the
ormation  of  platelet  microthrombi.15
In  a  nutshell  one  might  say  that  some  structural  or
iochemical  property  of  the  tumour  lesion  that  allows
ontinuous  exposure  of  blood  to  cancer  cells  and  their  pro-
oagulant  substances  appears  to  be  an  essential  component
f  TS  pathophysiology.
onclusion
his  report’s  goal  was  to  relate  a case  of  Trousseau’s
yndrome  associated  with  pancreatic  adenocarcinoma  diag-
osed  during  the  patient’s  stay  in  our  Internal  Medicine
ard.  Our  patient  displayed  recurrent  migratory  venous
hromboses,  beginning  in  his  extremities,  and  pulmonary
mbolism.  He  was  placed  on  LMWH  and  subsequently  showed
linical  improvement  regarding  the  thrombotic  processes.
he  authors  consider  that  the  24-h  hiatus  in  heparin  admin-
stration  around  the  time  of  the  liver  and  pancreatic  biopsies
ay  have  triggered  a  boost  of  thrombotic  activity,  leading
o  the  manifestation  of  an  ischaemic  stroke,  which  should
lert  us  to  the  massive  risk  of  suspending  heparin  in  these
ettings.
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